Spots Global Cancer Trial Database for fibroblast growth factor receptor inhibitor
Every month we try and update this database with for fibroblast growth factor receptor inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. |